MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 74 filers reported holding MARINUS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.41 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $186,301 | -48.0% | 27,000 | -70.0% | 0.01% | -53.3% |
| Q4 2022 | $358,200 | -94.5% | 90,000 | -90.8% | 0.03% | -94.0% |
| Q3 2022 | $6,484,000 | -29.5% | 975,000 | -48.7% | 0.50% | -22.8% |
| Q2 2022 | $9,196,000 | -49.1% | 1,900,000 | -1.7% | 0.65% | -32.9% |
| Q1 2022 | $18,072,000 | -21.3% | 1,932,829 | 0.0% | 0.97% | +14.4% |
| Q4 2021 | $22,961,000 | +4.5% | 1,932,829 | +0.2% | 0.84% | -1.4% |
| Q3 2021 | $21,963,000 | -36.6% | 1,929,929 | 0.0% | 0.86% | -28.3% |
| Q2 2021 | $34,623,000 | +18.1% | 1,929,929 | +1.9% | 1.20% | -22.9% |
| Q1 2021 | $29,309,000 | +31.9% | 1,893,400 | +4.0% | 1.55% | +47.6% |
| Q4 2020 | $22,218,000 | +77.9% | 1,821,149 | +87.4% | 1.05% | +15.0% |
| Q3 2020 | $12,486,000 | – | 971,718 | – | 0.91% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 3,629,622 | $33,936,000 | 7.88% |
| VR Adviser, LLC | 3,156,803 | $29,516,000 | 4.78% |
| Bleichroeder LP | 1,322,463 | $12,365,000 | 2.19% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $13,380,000 | 1.30% |
| 683 Capital Management, LLC | 1,932,829 | $18,072,000 | 0.97% |
| Granite Point Capital Management, L.P. | 472,056 | $4,414,000 | 0.92% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,766,000 | $25,862,000 | 0.79% |
| Avoro Capital Advisors LLC | 3,150,000 | $29,453,000 | 0.54% |
| Artal Group S.A. | 1,000,000 | $9,350,000 | 0.39% |
| Stonepine Capital Management, LLC | 56,747 | $531,000 | 0.22% |